Heart scan study sees if new drug clears sticky proteins
NCT ID NCT06073587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the drug eplontersen can reduce abnormal protein buildup in the heart for people with a condition called ATTR-CM. About 150 participants from a larger trial will get heart scans after 140 weeks of treatment. The goal is to see if the drug helps clear these proteins, which could slow heart damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Main Campus
Cleveland, Ohio, 44195, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Hospital Universitario Puerta de Hierro
Majadahonda, 28222, Spain
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.